Saturna Capital Corp Has $30.88 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Saturna Capital Corp grew its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 29.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,334,860 shares of the company's stock after purchasing an additional 307,039 shares during the period. Saturna Capital Corp owned approximately 0.07% of Kenvue worth $30,875,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in KVUE. Riverview Trust Co acquired a new position in Kenvue during the 3rd quarter valued at about $30,000. Ashton Thomas Securities LLC acquired a new position in shares of Kenvue during the third quarter valued at approximately $35,000. Studio Investment Management LLC raised its holdings in Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock worth $45,000 after purchasing an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators lifted its position in Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock worth $45,000 after purchasing an additional 651 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Kenvue during the 2nd quarter valued at $61,000. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Down 1.3 %

Shares of KVUE stock traded down $0.31 on Wednesday, reaching $23.13. 16,481,153 shares of the company's stock traded hands, compared to its average volume of 18,081,010. The company has a market capitalization of $44.35 billion, a P/E ratio of 41.95, a price-to-earnings-growth ratio of 2.15 and a beta of 1.36. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $23.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business's 50 day moving average price is $22.72 and its two-hundred day moving average price is $20.62.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the prior year, the company earned $0.31 EPS. The firm's quarterly revenue was down .4% on a year-over-year basis. On average, equities analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.55%. The ex-dividend date is Wednesday, November 13th. Kenvue's dividend payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price objective on Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Jefferies Financial Group began coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. UBS Group boosted their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Wednesday, August 7th. Finally, Royal Bank of Canada cut shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 target price for the company. in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Kenvue presently has an average rating of "Hold" and an average price target of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.